短程二维放疗姑息治疗食管癌的II期研究
在仅具备二维放疗技术的低资源环境中,开展II期试验评估2天内4次共12 Gy短程加速放疗对局部晚期或转移性食管癌的症状缓解效果。17例患者中,吞咽困难、反流、吞咽痛及胸背痛的姑息缓解率分别为76%、82%、69%和56%,未出现急性≥G3毒性。
要点
- 2天4次共12 Gy短程方案在二维技术下可行且耐受良好
- 吞咽困难与反流姑息缓解率分别为76%和82%
- 未观察到急性≥G3毒性,适合低资源中心缩短治疗时间
核心结论
- 短程加速放疗采用常规二维技术计划与实施,对局部晚期或转移性食管癌的症状姑息有效且耐受良好。
- 该方案可能有助于发展中国家的放疗中心缩短治疗时间、降低成本并减少治疗前等待时间。
研究设计与样本
- II期试验,基于Simon两阶段设计;共17例患者接受治疗(男/女=10/7,中位年龄50.0岁,范围27-78岁)。
- 放疗方案为总剂量12 Gy分4次、每日2次、共2天、间隔≥8小时,采用二维常规放疗技术,使用钴60装置(Equinox,Best Theratronics,Ottawa,Ontario)。
- 症状采用国际原子能机构评分系统分级。
主要发现
- 基线最常见症状为吞咽困难或反流(100%)、吞咽痛(76%)、胸痛或背痛(53%)。
- 放疗后1个月全部患者存活,吞咽困难、反流、吞咽痛、胸痛或背痛的姑息缓解率(完全加部分)分别为76%、82%、69%、56%。
- 无患者出现急性≥G3毒性。
关键数值与推荐
- 姑息缓解率定义为完全缓解加部分缓解:吞咽困难76%、反流82%、吞咽痛69%、胸痛或背痛56%(放疗后1个月)。
- 放疗剂量与分割:12 Gy分4次,每日2次,共2天,间隔≥8小时。
临床怎么用
- 在仅有二维放疗技术的低资源中心,可考虑采用2天4次共12 Gy短程方案姑息缓解食管癌相关症状。
- 治疗前应使用标准化评分系统评估吞咽困难、反流、吞咽痛及胸背痛,并在放疗后1个月评估缓解情况。
局限性
- 为单臂II期试验,样本量17例,未设对照组。
- 仅评估短期(1个月)姑息缓解与急性毒性,未报告长期疗效与晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locally advanced and metastatic esophageal cancer are usually affected by cancer-related symptoms, which worsen their performance status and quality of life. The aim of this study was to determine the efficacy of short-course accelerated radiation therapy for symptomatic palliation in a low resourced setting where only a 2-dimensional radiation therapy (RT) technique was available. METHODS AND MATERIALS: A phase II trial based on Simon's 2-stage design was planned. A total dose of 12 Gy in 4 fractions, twice per day, over 2 days, ≥8 hours apart, using a 2-dimensional conventional RT technique was delivered with a Cobalt 60 unit (Equinox, Best Theratronics, Ottawa, Ontario). Symptoms were graded using the International Atomic Energy Agency scoring system. RESULTS: A total of 17 patients were treated (male/female = 10/7; median age, 50.0 years; range, 27-78 years; histology: 6 adenocarcinomas and 11 squamous cell carcinomas; tumor site: 4 gastresophageal junction and 13 esophagus). The most frequent baseline symptoms were dysphagia or regurgitation (100%), odynophagia (76%), and chest or back pain (53%). At 1 month after RT, all patients were alive with palliative response rates (complete plus partial) for dysphagia, regurgitation, odynophagia, and chest or back pain of 76%, 82%, 69%, and 56%, respectively. No patients presented acute ≥G3 toxicity. CONCLUSIONS: Short-course accelerated radiation therapy treatment, planned and delivered using a conventional 2-dimensional RT technique, was effective and well tolerated for the symptomatic palliation of locally advanced or metastatic esophageal cancer. This schedule may be useful for RT centers in developing countries to reduce treatment times, costs, and patient waiting times before treatment.
引用
- Deressa BT, Tigeneh W, Bogale N, et al. Short-Course 2-Dimensional Radiation Therapy in the Palliative Treatment of Esophageal Cancer in a Developing Country: A Phase II Study (Sharon Project). Int J Radiat Oncol Biol Phys. 2019. PMID: 31622698. doi:10.1016/j.ijrobp.2019.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。